Get the Stockscreener App
126.61
0.80%
1.01
After Hours:
125.77
-0.84
-0.66%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $126.61, with a volume of 5.49M.
It is up +0.80% in the last 24 hours and down -6.88% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$125.60
Open:
$125.74
24h Volume:
5.49M
Relative Volume:
0.90
Market Cap:
$219.58B
Revenue:
$41.95B
Net Income/Loss:
$13.40B
P/E Ratio:
16.55
EPS:
7.65
Net Cash Flow:
$6.35B
1W Performance:
-0.64%
1M Performance:
-6.88%
6M Performance:
+12.31%
1Y Performance:
+13.55%
1-Day Range:
$125.13
$127.34
1-Week Range:
$124.50
$128.79
52-Week Range:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.61 | 219.58B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
102.34 | 151.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
367.77 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.23 | 115.57B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.09 | 41.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Diamond Hill Capital is Crazy About Abbott Laboratories (NYSE:ABT) - Insider Monkey
Behind the Scenes of Abbott Laboratories's Latest Options Trends - Benzinga
Abbott gets FDA nod to begin IVL trial after rivals buy up competition - MedTech Dive
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic - Yahoo Finance
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Abbott makes IVL move as FDA approves new clinical trial - Cardiovascular Business
Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US - Simply Wall St
Abbott gets green light for clinical trials of new heart treatment system - Crain's Chicago Business
Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries - Fierce Biotech
Abbott Laboratories Gets FDA Approval to Assess Investigational Device in Heart Disease Clinical Trial - Marketscreener.com
TD Cowen maintains $135 target for Abbott Labs stock, reiterates Buy - Investing.com
Abbott is making an IVL play with FDA IDE nod - Mass Device
FDA approves Abbott’s CAD treatment trial - Investing.com India
Abbott Wins FDA IDE Nod for Coronary IVL Trial - MPO-mag
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Lateral Flow Assays Market Analysis Report 2025-2030: Next-generation LFAs, Advancement in LFA Solutions and Reagents, and Rising Acceptance of POC Testing - GlobeNewswire Inc.
Jim Cramer On Abbott Laboratories (ABT): “Abbott Labs Stock Is Back on My Radar” - Insider Monkey
Global Glucose Biosensor Market Positioned for Accelerated - openPR
Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up - Yahoo Finance
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock? - MSN
Abbott Settles Suit on HIV-Testing Patent With Novartis, Grifols - Bloomberg Law
What Does the Market Think About Abbott Laboratories? - Benzinga India
Abbott’s world-first portable whole blood rapid test for concussions launches in the UK (2) - PharmiWeb.com
U.S. Clinical Nutrition Market Is Booming Worldwide 2025-2032 | - openPR
Abbott (ABT) Gains But Lags Market: What You Should Know - Yahoo Finance
Medtronic, Abbott Block Boston Scientific Heart Valve IP - Law360
Abbott launches portable concussion blood test in UK - Medical Device Network
Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating! - Smartkarma
Brazil Enteral Nutrition Market Is Booming Worldwide 2025-2032 - openPR
Medical Nutrition Market Key Players Analysis- Abbott - openPR
RFK Jr.’s Next Targets Are Companies Making Baby Formula - Yahoo Finance
US health agencies announce plan to strengthen infant formula supply and quality -March 18, 2025 at 02:23 pm EDT - Marketscreener.com
Abbott Laboratories (ABT): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Decoding Abbott Laboratories's Options Activity: What's the Big Picture? - Benzinga
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq
Personalized Vitamins Market Top Players- BASF SE, Abbott Laboratories. Amway Corporation, Bayer AG, Caligenix. - openPR
Abbott's Narrow Economic Moat Rests on a Solid Product Portfolio - Morningstar
Abbott Stock Could Be On The Verge Of A Breakout — Here’s What Smart Money Sees (NYSE:ABT) - Seeking Alpha
Reckitt’s Mead Johnson, Abbott to face new trial in US infant-formula case - just-food.com
Abbott Laboratories Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) earnings growth rate lags the 15% CAGR delivered to shareholders - Simply Wall St
Abbott Laboratories Basking In A Sharp Turn In Sentiment (NYSE:ABT) - Seeking Alpha
Why Abbott Laboratories (ABT) Went Down On Thursday? - MSN
Why Abbott Laboratories (ABT) Went Down On Friday? - Insider Monkey
Abbott Labs, Reckitt Benckiser Shares Fall After New Ruling on Infant Formula Case - The Wall Street Journal
Baby Formula Makers Abbott and Reckitt See Stocks Slide as Judge Allows Retrial - Investopedia
In a setback for Abbott Laboratories, judge allows new trial in case over formula for premature infants - Chicago Tribune
Judge Vacates Baby Formula Trial Win For Abbott, Mead - Law360
‘A Manifest Injustice': Judge Who Sanctioned Abbott’s Counsel Grants New Infant Formula Trial - Law.com
Sector Update: Health Care -March 14, 2025 at 03:29 pm EDT - Marketscreener.com
BofA keeps $150 target on Abbott Labs stock amid retrial news - Investing.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):